Active Specific Immunotherapy for Melanoma: Phase I Trial of Allogeneic Lysates and a Novel Adjuvant

Cancer Research

Volumn 48, Issue 20, 1988, Pages 5883-5893

  Mitchell, Malcolm S ^a   Kan Mitchell, June ^a   Kempf, Raymond A ^a   Harel, William ^a   Shau, Hungyi ^a   Lind, Susan ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CELL EXTRACT; PHOSPHORYL LIPID A; TUMOR ANTIGEN;

AGE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; DRUG EVALUATION; FEMALE; HUMAN; HYPERSENSITIVITY, DELAYED; IMMUNIZATION, PASSIVE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0023686538     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Menck. H., and Henderson, B. E. Cancer incidence in the Pacific basin. Natl. Cancer Inst. Monogr., 69: 105-111, 1985.
2. Cummings, F. J., McDonald, C. J., and Calabresi, P. Melanoma. In: P. Calabresi, P. Schein, and S. A. Rosenberg (eds.), Medical Oncology, pp. 650-679. New York: MacMillan and Co., 1985.
3. Kirkwood, J. M., and Ernstoff, M. E. Potential applications of the interferons in oncology: Lessons drawn from studies of human melanoma. Semin. Oncol., 13 (Supp 2): 48-56, 1986.
4. Mitchell, M. S., Kempf, R. A., Harel, W., Shau, H., Boswell, W. D., Lind, S., and Bradley, E. C. Effectiveness and tolerability of low-dose cyclophos phamide and low-dose intravenous interleukin-2 in the treatment of dissem inated melanoma. J. Clin. Oncol., 6: 409-424, 1988.
5. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl. J. Med., 316: 889-897, 1987.
6. Kahan, B. D., Pellis, N. R., LeGrue, S. J., and Tanaka, T. Immunotherapeutic effects of tumor-specific transplantation antigens released by 1-butanol. Cancer (Phila.), 49: 1168-1173, 1982.
7. LeGrue, S. J., Allison, J. P., Macek, C. M., Pellis, N. R., and Kahan, B. D. Immunobiological properties of 1-butanol-extracted cell surface antigens. Cancer Res., 41: 3956-3960, 1981.
8. LeGrue, S. J., Kahan, B. D., and Pellis, N. R. Extraction of a murine tumor specific transplantation antigen with l-butanol. I. Partial purification by isoelectric focusing. J. Natl. Cancer Inst., 65: 191-196, 1980.
9. Bystryn, J. C., Jacobsen, S., Harris, M., Roses, D., Speyer, J., and Levin, M. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J. Biol. Response Modif., 5: 211-224, 1986.
10. Berd, D., Maguire, H. C., Jr., and Mastrangelo, M. J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res., 44: 5439-5443, 1984.
11. Berd, D., Maguire, H. C., Jr., and Mastrangelo, M. J. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res., 44: 1275-1280, 1984.
12. Livingston, P., Takeyama, H., Pollack, M. S., Houghton, A. N., Albino, A., Pinsky, C. M., et al. Serological responses of melanoma patients to vaccine derived from allogeneic cultured melanoma cells. Int. J. Cancer, 31: 567-575, 1983.
13. Ribi, E., Cantrell, J. L., Takayama, K., Qureshi, N., Peterson, J., and Ribi, H. O. Lipid A and immunotherapy. Rev. Infect. Dis., 6: 567-572, 1984.
14. Harper, J. R., Bumol, T. F., and Reisfeld, R. A. Serological and biochemical analyses of monoclonal antibodies to human melanoma-associated antigens. Hybridoma, 1: 423-432, 1982.
15. Vosika, G., Schmidtke. J., Goldman, A., Parker, R., Ribi, E., and Gray. G. R. Phase I-II study of intralesional immunotherapy with oil attached Myco bacterium smegmatis cell wall skeleton and trehalose dimycolate. Cancer Immunol. Immunother., 6: 135-142, 1979.
16. Vosika, G., Giddings, C., and Gray, G. R. Phase 1 study of intravenous mycobacterial cell wall skeleton and trehalose dimycolate attached to oil droplets. J. Biol. Response Modif., 3: 620-626, 1984.
17. Vose, B. M. Quantitation of proliferativi and cytotoxic precursor cells directed against human tumors: Limiting dilution analysis in peripheral blood and at the tumor site. Int. J. Cancer, 30: 135-142, 1982.
18. Taswel. C. Limiting dilutions assays for the determination of immunocom petent cell frequencies. I. Data analysis. J. Immunol., 126: 1614-1619, 1981.
19. Fazekas de St. Groth, S. The evaluation of limiting dilution assays. J. Immunol. Methods, 49: R11-R23, 1982.
20. Hard, W., and Nelken, D. An enzyme immunoassay for detection of anti sperm antibodies. Am. J. Reprod. Immunol. Microbiol., 8: 137-140. 1985.
21. Berd, D., Maguire. H. C., Jr., and Mastrangelo. M. J. Induction of cell mediated immunity to autologoiTs melanoma cells and regression of metatases after treatment with a melanoma cell vaccine preceded by cyclophos phamide. Cancer Res., 46: 2572-2577, 1986.
22. Berd, D., and Mastrangelo, M. J. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest., in press, 1988.
23. Neidhart, J. A., Murphy, S. G., Hennick, L. A., and Wise, H. A. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer (Phila.), 46: 1128-1134, 1980.
24. McCune, C. S., Schapira, D. V., and Henshaw, E. C. Specific immunotherapy of advanced renal carcinoma: Evidence for the polyclonality of metastases. Cancer, 47: 1984-1987. 1981.
25. Sahasrabudhe, D. M., de Kernion, J. B., Pontes. J. E., McCune, C. S., Ryan, D. M., O'Donnell, R. W., et al. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Response Modif., 5: 581-594, 1986.
26. Hanna, M. G., Jr., and Hoover, H. C., Jr. Active specific immunotherapy as an adjunct to the treatment of metastatic solid tumors. In: A. E. Reif, and M. S. Mitchell (eds.). Immunity to Cancer, pp. 429-440. Orlando: Academic Press, 1985.
27. Hoover, H. C., Jr., Surdyke, M. G., Dangel, R. B., Peters, L. C., and Hanna, M., Jr. Prospectively randomized trial of adjuvant active-specific immuno therapy for human colorectal cancer. Cancer (Phila.), 55: 1236-1243, 1985.
28. Lanier, L. L., Le, A. M., Cwirla, S., Federspiel, N., and Phillips, J. H. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex. Fed. Proc., 45: 2823-2828, 1986.
29. Lanier, L. L., and Phillips, J. H. Evidence for three types of human cytotoxic lymphocytes. Immunol. Today, 7: 132-134. 1986.
30. Zinkernagel, R. M., and Doherty, P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semial logeneic system. Nature (Lond.), 248: 701-702, 1974.
31. Boylston, A. W. The T-cell antigen receptor gamma chain and its accomplices. Immunol. Today, 8: 144-146, 1987.
32. Hayashi, H., Tanaka, K., Jay, F., Khouri, G., and Jay, G. Modulation of the tumorigenicity of human adenovirus-12-transformed cells by interferon. Cell, 43: 263-267, 1985.
33. Weber, J. S., Jay, G., Tanaka, K., and Rosenberg, S. A. Immunotherapy of a murine tumor with interleukin-2. Increased sensitivity after major histo compatibility complex class I gene transfection. J. Exp. Med., 166: 1716-1733, 1987.